Zydus Cadila gets tentative USFDA nod to market lung cancer drug

Zydus Cadila gets tentative USFDA nod to market lung cancer drug
PTI
New Delhi |
Updated on
June 03, 2021
The drug to be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Osimertinib tablets, used to treat lung cancer.
The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Osimertinib tablets in the strengths of 40 mg and 80 mg, Zydus Cadila, part of the Cadila Healthcare group, said in a regulatory filing.
Osimertinib is used to treat lung cancer. Osimertinib works by slowing or stopping the growth of cancer cells.

Related Keywords

Ahmedabad ,Gujarat ,India ,Zydus Cadila ,Drug Administration ,Cadila Healthcare ,Tentative Approval ,Us Health Regulator ,Osimertinib Tablets ,Lung Cancer ,Abbreviated New Drug Applications ,அஹமதாபாத் ,குஜராத் ,இந்தியா ,ஜய்துச் காடிலா ,காடிலா சுகாதாரம் ,எங்களுக்கு ஆரோக்கியம் சீராக்கி ,நுரையீரல் புற்றுநோய் ,